Phase III clinical trials: tPA in the experimental setting
نویسندگان
چکیده
Dr. Gladstone is a Stroke Fellow in the Division of Neurology, Department of Medicine, Sunnybrook and Women’s College Health Sciences Centre, and is a trainee in the Royal College of Physicians and Surgeons of Canada’s Clinician Investigator Program at the University of Toronto, Toronto, Ont. Dr. Black is Head, Division of Neurology, and Codirector, Stroke Research Unit, Sunnybrook and Women’s College Health Sciences Centre, and is Professor of Medicine (Neurology), University of Toronto, Toronto, Ont.
منابع مشابه
Characteristics of Clinical Trials in Iran: A Sample of 5000 Trials Registered in IRCT
Background and Objectives: A considerable number of clinical trials are conducted in Iran each year. Not much is known about the characteristics of them, this study aimed to investigate key characteristics of Iranian clinical trials. Methods: All clinical trial protocols registered in IRCT until November 2013 were selected. Text mining techniques were used to extract information from data t...
متن کاملAcute stroke thrombolysis with intravenous tissue plasminogen activator in an Australian tertiary hospital.
OBJECTIVE To report initial experience with the use of intravenous tissue plasminogen activator (tPA) to treat acute ischaemic stroke at an Australian tertiary-care hospital. DESIGN Retrospective audit of computerised hospital stroke database. PARTICIPANTS AND SETTING All patients with acute ischaemic stroke treated with intravenous tPA between April 1999 and July 2002 at the Royal Melbourn...
متن کاملBevacizumab in the treatment of metastatic colorectal cancer.
Angiogenesis is essential for tumor growth and metastasis, and has become a useful target for novel biological agents. Vascular endothelial growth factor (VEGF) is one of the most important angiogenesis regulators. Bevacizumab is a recombinant humanized anti-VEGF monoclonal antibody recently approved in Europe and the USA for first- and second-line therapy (in combination with chemotherapy) for...
متن کاملPicking the winners in a sea of plenty.
PURPOSE Selecting an experimental arm for a Phase III trial is based on the results of Phase II investigations. Historical results show that this paradigm leads to the failure of many experimental therapies in the Phase III setting. This is the result of failures in the Phase II design that include differences in the patient populations and basing sample size determinations on levels of benefit...
متن کاملEndovascular Mechanical Thrombectomy for Acute Ischemic Stroke: A New Standard of Care
The treatment of acute ischemic stroke (AIS) in the setting of intracranial large artery occlusion (LAO) with intravenous tissue plasminogen activator (IV-tPA) is associated with low rates of recanalization and high rates of neurological morbidity and functional dependence. Endovascular intervention, particularly mechanical thrombectomy, is a promising therapeutic adjunct to IV-tPA for the trea...
متن کامل